

Pneumococcal Vaccine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

<https://marketpublishers.com/r/P2A525022CB1EN.html>

Date: March 2025

Pages: 130

Price: US\$ 4,850.00 (Single User License)

ID: P2A525022CB1EN

Abstracts

The Global Pneumococcal Vaccine Market was valued at USD 8.8 billion in 2024 and is projected to grow at a CAGR of 5.6% between 2025 and 2034. Several factors are driving this growth, including the increasing prevalence of pneumococcal infections, rising public awareness about the importance of vaccination, and favorable government initiatives promoting immunization programs worldwide. The surge in vaccination rates can be attributed to growing efforts by healthcare authorities to implement mandatory vaccination schedules, particularly for children and high-risk populations. Ongoing advancements in research and development are leading to the production of more effective and innovative pneumococcal vaccines, catering to a wider range of serotypes. These vaccines play a crucial role in reducing the incidence of life-threatening conditions such as pneumonia, meningitis, and sepsis caused by *Streptococcus pneumoniae*.

As governments prioritize preventive healthcare and integrate pneumococcal vaccines into routine immunization schedules, market demand is set to rise significantly. The increasing focus on immunizing immunocompromised individuals and elderly populations is creating new opportunities for vaccine manufacturers. Furthermore, pharmaceutical companies are working closely with global health organizations to expand access to these vaccines in low-income regions, where pneumococcal diseases remain a major public health concern. Rising funding for vaccine research, coupled with initiatives to develop broad-spectrum vaccines that cover emerging serotypes, is expected to further boost market growth over the next decade.

The market is segmented based on product, with various pneumococcal vaccines contributing significantly to preventing severe bacterial infections. One of the most widely used vaccines is expected to experience notable growth, with a projected CAGR of 5.8%, generating USD 7.9 billion by 2034. Its proven efficacy in protecting against

multiple *Streptococcus pneumoniae* serotypes has led to widespread adoption, especially in pediatric and high-risk adult populations. The vaccine's ability to provide long-term immunity makes it a preferred choice among healthcare providers and government vaccination campaigns. With its broad coverage against severe pneumococcal diseases, including pneumonia, sepsis, and meningitis, this vaccine continues to strengthen its position in global immunization programs.

The pneumococcal vaccine market is divided into two main types: conjugate vaccines and polysaccharide vaccines. Conjugate vaccines dominated the market in 2024, generating USD 8 billion due to their ability to offer long-lasting protection against pneumococcal infections. Their high effectiveness in preventing pneumococcal diseases, especially among children under five years old, has fueled their growing demand. Additionally, expanding applications among adult populations, particularly those with weakened immune systems and elderly individuals, are accelerating the adoption of conjugate vaccines. Their ability to reduce the overall burden of pneumococcal diseases has established them as the preferred choice for routine immunization schedules.

The U.S. pneumococcal vaccine market generated USD 3.7 billion in 2024. The rising elderly population in the country has been a key driver of this growth, as aging individuals face a higher risk of contracting pneumococcal infections due to declining immune function. Preventive healthcare efforts and nationwide vaccination programs have significantly increased vaccine uptake, ensuring better protection for high-risk populations. Pharmaceutical companies and government agencies continue to enhance vaccine coverage, with ongoing efforts to develop newer vaccines that target a broader range of pneumococcal serotypes, further supporting the market's long-term expansion.

Contents

CHAPTER 1 METHODOLOGY AND SCOPE

- 1.1 Market scope and definitions
- 1.2 Research design
 - 1.2.1 Research approach
 - 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
 - 1.3.1 Base year calculation
 - 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
 - 1.5.1 Primary sources
 - 1.5.2 Data mining sources

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Industry 360° synopsis

CHAPTER 3 INDUSTRY INSIGHTS

- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
 - 3.2.1 Growth drivers
 - 3.2.1.1 Increasing prevalence of pneumococcal diseases
 - 3.2.1.2 Government immunization programs and initiatives
 - 3.2.1.3 Growing aging population
 - 3.2.1.4 Technological advancements and new product launches
 - 3.2.2 Industry pitfalls and challenges
 - 3.2.2.1 High cost of vaccines
 - 3.2.2.2 Vaccine hesitancy and low awareness
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technology landscape
- 3.6 Pipeline analysis
- 3.7 Future market trends
- 3.8 Gap analysis
- 3.9 Porter's analysis

3.10 PESTEL analysis

CHAPTER 4 COMPETITIVE LANDSCAPE, 2024

- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard

CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY PRODUCT, 2021 – 2034 (\$ MN)

- 5.1 Key trends
- 5.2 Pneumosil (PCV10)
- 5.3 Pneumovax 23 (PPSV23)
- 5.4 Prevnar 13 (PCV13)
- 5.5 Prevnar 20 (PCV20)
- 5.6 Synflorix (PCV10)
- 5.7 Vaxneuvance (PCV15)
- 5.8 Other products

CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY VACCINE TYPE, 2021 – 2034 (\$ MN)

- 6.1 Key trends
- 6.2 Pneumococcal conjugate vaccines (PCV)
- 6.3 Pneumococcal polysaccharide vaccines (PPSV)

CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY AGE GROUP, 2021 – 2034 (\$ MN)

- 7.1 Key trends
- 7.2 Infants and children (0–5 years)
- 7.3 Adults (18–64 years)
- 7.4 Elderly (65+ years)

CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY DISTRIBUTION

CHANNEL, 2021 – 2034 (\$ MN)

- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Retail pharmacies
- 8.4 Government and public health agencies
- 8.5 E-commerce

CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2034 (\$ MN)

- 9.1 Key trends
- 9.2 North America
 - 9.2.1 U.S.
 - 9.2.2 Canada
- 9.3 Europe
 - 9.3.1 Germany
 - 9.3.2 UK
 - 9.3.3 France
 - 9.3.4 Spain
 - 9.3.5 Italy
 - 9.3.6 Netherlands
- 9.4 Asia Pacific
 - 9.4.1 China
 - 9.4.2 Japan
 - 9.4.3 India
 - 9.4.4 Australia
 - 9.4.5 South Korea
- 9.5 Latin America
 - 9.5.1 Brazil
 - 9.5.2 Mexico
 - 9.5.3 Argentina
- 9.6 Middle East and Africa
 - 9.6.1 South Africa
 - 9.6.2 Saudi Arabia
 - 9.6.3 UAE

CHAPTER 10 COMPANY PROFILES

- 10.1 Beijing Minhai Biological Technology
- 10.2 Bio-Manguinhos/Fiocruz
- 10.3 GlaxoSmithKline
- 10.4 Merck & Co.
- 10.5 Pfizer
- 10.6 Serum Institute of India
- 10.7 Walvax Biotechnology

I would like to order

Product name: Pneumococcal Vaccine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

Product link: <https://marketpublishers.com/r/P2A525022CB1EN.html>

Price: US\$ 4,850.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P2A525022CB1EN.html>